Bayer bets on gene therapy with Dimension deal

June 23, 2014 11:42 AM

16 0

Bayer bets on gene therapy with Dimension deal

FRANKFURT/LONDON (Reuters) - Bayer has struck an alliance with U.S. biotech firm Dimension Therapeutics to develop a gene therapy for the treatment of haemophilia A, marking renewed interest in an approach to tackle the cause of diseases at a cellular level.

Gene therapy involves inserting corrective genes into malfunctioning cells to get them to work again without further use of drugs. Dimension has been looking into using viruses to carry the genes to the affected cells.Gene therapy has seen more than 20 years of experiments and a series of disappoint...

Also read: Lyft, Magna in Deal to Develop Hardware, Software for Self-Driving Cars

Read more

To category page